UK authority rejects notion of niche specialisation
This article was originally published in Clinica
The UK regulatory agency for medical devices, the Medicines and Healthcare products Regulatory Agency (MHRA), intends to maintain a leading position on all issues of medical device regulation and not just specialise in certain areas.
You may also be interested in...
Oncology R&D isn’t waning, but investment in neurology and psychiatry drug development are paying off in new drug approvals. Rapid growth in CDER non-malignant hematology approvals reflects longer, broader trend toward orphan drugs.
We clean out your Martin Luther King Day inbox so you don't have to.
Political worries aside, industry is confidently executing on focused strategies as it welcomes a new decade, even if a lack of deal news at the J.P. Morgan Healthcare Conference didn't excite investors.